IDH2 and glioblastoma: Unfortunately, this study was performed in the context of histopathologic diagnosis of glioblastoma, and these subtypes are based on the presence of IDH mutation and are therefore no longer used clinically, though novel classifications of the tumor microenvironment with bulk RNA sequencing continue to be evaluated [79].